NLRC5/CITA: A Key Player in Cancer Immune Surveillance

详细信息    查看全文

• 作者：Sayuri Yoshihama¹ ; ² ; Saptha Vijayan¹ ; Tabasum Sidiq¹ ; Koichi S. Kobayashi¹ ; ^{kobayashi@medicine.tamhsc.edu}
• 关键词：MHC class I ; NLRC5 ; CITA ; cancer ; immune evasion
• 刊名：Trends in Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：3
• 期：1
• 页码：28-38
• 全文大小：2465 K
• 卷排序：3

文摘

Cancer cells need to escape immune surveillance for successful tumor growth. Loss of MHC class I has been described as a major immune evasion strategy in many cancers. MHC class I transactivator (CITA), NLRC5 [nucleotide-binding domain and leucine-rich repeats containing (NLR) family, caspase activation and recruitment domain (CARD) domain containing 5], is a key transcription coactivator of MHC class I genes. Recent genetic studies have revealed that NLRC5 is a major target for cancer immune evasion mechanisms. The reduced expression or activity of NLRC5 caused by promoter methylation, copy number loss, or somatic mutations is associated with defective MHC class I expression, impaired cytotoxic T cell activation, and poor patient prognosis. Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.